风险最小化措施对欧洲雷奈酸锶使用的影响:五国多国队列研究
该研究由EU-ADR联盟在5个欧洲国家开展多国多数据库队列研究,评估EMA于2013年5月和2014年3月发布的雷奈酸锶风险最小化措施(RMM)对药物使用的影响。结果显示,雷奈酸锶平均月患病率下降86.4%,发病率下降97.3%,无禁忌症且符合限制性适应症的患者比例增加。
要点
- 雷奈酸锶月患病率从参考期62.6/10,000人年降至评估期8.5/10,000人年,下降86.4%。
- 雷奈酸锶发病率从7.4/10,000人年降至0.2/10,000人年,下降97.3%。
- 评估期符合限制性适应症且无禁忌症的患者比例增加,但1年持续治疗率下降。
核心结论
- 欧盟限制雷奈酸锶使用的监管措施产生显著效果,总体使用量大幅下降。
- RMM实施后,符合限制性适应症且无禁忌症的患者比例增加,但1年持续治疗率下降。
研究设计与样本
- 多国、多数据库队列研究,数据来源包括丹麦医院电子病历数据库及意大利、西班牙、荷兰、英国的初级保健数据库。
- 比较三个时期:参考期(2004年至2013年5月)、过渡期(2013年6月至2014年3月)和评估期(2014年4月至2016年底)。
主要发现
- 雷奈酸锶平均月患病率从参考期62.6/10,000人年(95%CI 62.4-62.9)降至评估期8.5/10,000人年(95%CI 8.5-8.6),下降86.4%。
- 雷奈酸锶发病率从参考期7.4/10,000人年(95%CI 7.4-7.4)降至评估期0.2/10,000人年(95%CI 0.2-0.2),下降97.3%。
- 任何禁忌症的患病率在各时期下降,而限制性适应症的患病率增加。
- 与参考期相比,评估期1年持续治疗率下降。
关键数值与推荐
- RMM新增禁忌症包括:缺血性心脏病、外周动脉疾病、脑血管疾病、未控制的高血压。
- RMM将雷奈酸锶适应症限制为严重骨质疏松症,须由经验丰富的医生启动,且不作为一线抗骨质疏松治疗。
临床怎么用
- 临床应遵循RMM要求,仅将雷奈酸锶用于严重骨质疏松症且无禁忌症的患者,并由经验丰富的医生启动。
- 处方前需评估心血管禁忌症(缺血性心脏病、外周动脉疾病、脑血管疾病、未控制高血压)。
- 需关注雷奈酸锶持续治疗率下降的趋势,加强患者随访与依从性管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In May 2013 and March 2014, the European Medicines Agency (EMA) issued two decisions restricting the use of strontium ranelate (SR). These risk minimisation measures (RMM) introduced new contraindications and limited the indications of SR therapy. The EMA required an assessment of the impact of RMMs on the use of SR in Europe. Methods design: multi-national, multi-database cohort Setting: electronic medical record databases based on hospital (Denmark) and primary care provenance (Italy, Spain, the Netherlands, UK). PARTICIPANTS: the database source populations were included for population-based analyses, and SR users for patient-level analyses. INTERVENTION: New RMMs included contraindications (ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, uncontrolled hypertension) and restricted SR indication to severe osteoporosis with initiation by experienced physician and not as first line anti-osteoporosis therapy. METHODS: Prevalence and incidence rates of SR use in the population; prevalence of contraindications and restricted indications in SR users, plus 1-year therapy persistence. Drug use measures were calculated in three periods for comparison: reference (2004 to May 2013), transition (June 2013 to March 2014) and assessment (from April 2014 to end 2016). RESULTS: The study population included 143 million person-years(PY) of follow-up and 76,141 incident episodes of SR treatment. Average monthly prevalence rates of SR use dropped by 86.4% from 62.6/10,000 PY (95 CI 62.4-62.9) in the reference to 8.5 (8.5-8.6) in the assessment period. Similarly, the incidence rate of SR use fell by 97.3% from 7.4/10,000 PY (7.4-7.4) to 0.2 (0.2-0.2) between the reference and assessment period. The prevalence of any contraindication decreased, whilst the prevalence of restricted indications increased in these periods. One-year persistence decreased in the assessment compared with reference period. CONCLUSIONS: Our study demonstrates a substantial impact of the regulatory action to restrict use of SR in Europe: SR utilisation overall decreased strongly. The proportion of patients fulfilling the restricted indications, without contraindications, increased after the proposed RMMs.
引用
- Berencsi K, Sami A, Ali MS, et al. Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int. 2019. PMID: 31696274. doi:10.1007/s00198-019-05181-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。